Drug intelligence / Profile preview

NPI-003

Development stage: Unknown
Lead developer: Nacuity Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

NPI-003 is a small molecule antioxidant pharmaceutical developed by Nacuity Pharmaceuticals for the treatment of nephropathic cystinosis. It is designed to address the accumulation of cystine crystals in various tissues, a hallmark of the disease, by acting as an antioxidant.

Beyond the preview

Go deeper on NPI-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPI-003.

Explore the full profile